Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 3,44 MB, PDF-dokument

  • Omid Rezahosseini
  • Sebastian Rask Hamm
  • Laura Pérez-Alós
  • Dina Leth Møller
  • Johannes Roth Madsen
  • Annemette Hald
  • Jose Juan Almagro Armenteros
  • Mia Marie Pries-Heje
  • Rasmus Bo Hasselbalch
  • Kamille Fogh
  • Erik Sørensen
  • Allan Rasmussen

Introduction: We investigated humoral and T-cell responses within 12 months after first BNT162b2 vaccine in solid organ transplant (SOT) recipients and controls who had received at least three vaccine doses. Furthermore, we compared the immune response in participants with and without previous SARS-CoV-2 infection. Methods: We included adult liver, lung, and kidney transplant recipients, and controls were selected from a parallel cohort of healthcare workers. Results: At 12th-month, the IgG geometric mean concentrations (GMCs) (P<0.001), IgA GMCs (P=0.003), and median IFN-γ (P<0.001) were lower in SOT recipients than in controls. However, in SOT recipients and controls with previous infection, the neutralizing index was 99%, and the IgG, and IgA responses were comparable. After adjustment, female-sex (aOR: 3.6, P<0.009), kidney (aOR: 7.0, P= 0.008) or lung transplantation (aOR: 7.5, P= 0.014), and use of mycophenolate (aOR: 5.2, P=0.03) were associated with low IgG non response. Age (OR:1.4, P=0.038), time from transplantation to first vaccine (OR: 0.45, P<0.035), and previous SARS-CoV-2 infection (OR: 0.14, P<0.001), were associated with low IgA non response. Diabetes (OR:2.4, P=0.044) was associated with T-cell non response. Conclusion: In conclusion, humoral and T-cell responses were inferior in SOT recipients without previous SARS-CoV-2 infection but comparable to controls in SOT recipients with previous infection.

TidsskriftFrontiers in Immunology
Antal sider15
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
OR received a grant from Rigshospitalet related to this work, and a grant from AP Møller Fonden not related to this work. MP received a grant from Roche, non-financial support from Boehringer Ingelheim, personal fees from Mallinckrodt, Novartis, GSK, and Astra-Zeneca not related to this work. ZH received a grant from Independent Research Fund. SS reported other non-financial relations with Alexion, Hansa Biopharma, and Corline Biomedical, outside the submitted work. PG received grants from The Carlsberg Foundation, the Novo Nordisk Foundation and the Svend Andersen Foundation related to this work. SN received unrestricted research grants from Novo Nordisk Foundation and Independent Research Fund.

Funding Information:
This work was supported by the Research Foundation of Rigshospitalet and grants from the Carlsberg Foundation (grant no. CF20-0045), the Novo Nordisk Foundation (grant no. NFF205A0063505 and grant no. NNF20SA0064201) and The Svend Andersen Research Foundation (grant no. SARF2021). Acknowledgments

Publisher Copyright:
Copyright © 2023 Rezahosseini, Hamm, Heftdal, Pérez-Alós, Møller, Perch, Madsen, Hald, Hansen, Armenteros, Pries-Heje, Hasselbalch, Fogh, Frikke-Schmidt, Hilsted, Sørensen, Ostrowski, Harboe, Iversen, Bundgaard, Sørensen, Rasmussen, Garred and Nielsen.

Antal downloads er baseret på statistik fra Google Scholar og

Ingen data tilgængelig

ID: 335964856